Reduced Breast Cancer Risk in Women With A History of Pre-Eclampsia: Implications of Postmenopausal Hormone Therapy
Clicks: 4
ID: 321578
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
0.9
/100
4 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #59 of 362 articles by views in the journal of clinical endocrinology & metabolism
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 362 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
CONTEXT: Both prior pre-eclamptic pregnancy and menopausal hormone therapy (MHT) are determinants for breast cancer (BC). OBJECTIVE: To study the effects of prior pre-eclampsia and MHT use on BC risk. DESIGN: Register-based cohort study with follow-up for BC (Finnish Cancer Register 1987-2023) and MHT use (National Reimbursement Register 1994-2019). SETTING: Nationwide population-based study in Finland. PARTICIPANTS: Women with prior pre-eclampsia (n = 31 688) and age-matched control women without pre-eclampsia (n = 91 726) who had given birth in 1969-1993. INTERVENTION: The BC risks were compared between prior pre-eclamptic and control women and between prior pre-eclamptic MHT users and non-users. RESULTS: Breast cancer occurred less frequently (p = 0.02) in prior pre-eclamptic women (6.6%, n = 2095) than in the controls (7.0%, n = 6410). The age-adjusted BC risk in prior pre-eclamptic women (aHR=0.89, 95% CI 0.83-0.94) was reduced. No clinical characteristics from pre-eclamptic pregnancy (e.g. severity) predicted the magnitude of the BC risk reduction.MHT use was accompanied with comparable BC risk rise in prior pre-eclamptic and control women (1.25, 1.12-1.40 vs. 1.30, 1.18-1.42). The increased risk with any MHT use was seen in both cohorts already after 5 years. This was primarily associated to estrogen-progestogen use, whereas estrogen only was not associated with BC risk in prior pre-eclamptic women. CONCLUSIONS: BC risk is reduced in women with a history of pre-eclampsia. The MHT-associated increase in BC risk is similar among women with or without a history of pre-eclampsia. Thus, pre-eclampsia is no contraindication for the use of MHT.
| Reference Key |
openalex_W7169681182
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Johanna Joensuu, Olavi Ylikorkala, Heli Siitonen, Hanna Savolainen‐Peltonen, Tomi S. Mikkola |
| Journal | the journal of clinical endocrinology & metabolism |
| Year | 2026 |
| DOI |
10.1210/clinem/dgag271
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.